Cargando…

Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1

BACKGROUND: Platelet aggregation during aspirin treatment displays considerable inter-individual variability. A genetic etiology likely exists, but it remains unclear to what extent genetic polymorphisms determine platelet aggregation in aspirin-treated individuals. AIM: To identify platelet-related...

Descripción completa

Detalles Bibliográficos
Autores principales: Würtz, Morten, Nissen, Peter H., Grove, Erik Lerkevang, Kristensen, Steen Dalby, Hvas, Anne-Mette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216141/
https://www.ncbi.nlm.nih.gov/pubmed/25360888
http://dx.doi.org/10.1371/journal.pone.0111816
_version_ 1782342221030227968
author Würtz, Morten
Nissen, Peter H.
Grove, Erik Lerkevang
Kristensen, Steen Dalby
Hvas, Anne-Mette
author_facet Würtz, Morten
Nissen, Peter H.
Grove, Erik Lerkevang
Kristensen, Steen Dalby
Hvas, Anne-Mette
author_sort Würtz, Morten
collection PubMed
description BACKGROUND: Platelet aggregation during aspirin treatment displays considerable inter-individual variability. A genetic etiology likely exists, but it remains unclear to what extent genetic polymorphisms determine platelet aggregation in aspirin-treated individuals. AIM: To identify platelet-related single nucleotide polymorphisms (SNPs) influencing platelet aggregation during aspirin treatment. Furthermore, we explored to what extent changes in cyclooxygenase-1 activity and platelet activation may explain such influence. METHODS: We included 985 Danish patients with stable coronary artery disease treated with aspirin 75 mg/day mono antiplatelet therapy. Patients were genotyped for 16 common SNPs in platelet-related genes using standard PCR-based methods (TaqMan). Platelet aggregation was evaluated by whole blood platelet aggregometry employing Multiplate Analyzer (agonists: arachidonic acid and collagen) and VerifyNow Aspirin. Serum thromboxane B(2) was measured to confirm aspirin adherence and was used as a marker of cyclooxygenase-1 activity. Soluble P-selectin was used as marker of platelet activation. Platelet aggregation, cyclooxygenase-1 activity, and platelet activation were compared across genotypes in adjusted analyses. RESULTS: The A-allele of the rs12041331 SNP in the platelet endothelial aggregation receptor-1 (PEAR1) gene was associated with reduced platelet aggregation and increased platelet activation, but not with cyclooxygenase-1 activity. Platelet aggregation was unaffected by the other SNPs analyzed. CONCLUSION: A common genetic variant in PEAR1 (rs12041331) reproducibly influenced platelet aggregation in aspirin-treated patients with coronary artery disease. The exact biological mechanism remains elusive, but the effect of this polymorphism may be related to changes in platelet activation. Furthermore, 14 SNPs previously suggested to influence aspirin efficacy were not associated with on-aspirin platelet aggregation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01383304
format Online
Article
Text
id pubmed-4216141
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42161412014-11-05 Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1 Würtz, Morten Nissen, Peter H. Grove, Erik Lerkevang Kristensen, Steen Dalby Hvas, Anne-Mette PLoS One Research Article BACKGROUND: Platelet aggregation during aspirin treatment displays considerable inter-individual variability. A genetic etiology likely exists, but it remains unclear to what extent genetic polymorphisms determine platelet aggregation in aspirin-treated individuals. AIM: To identify platelet-related single nucleotide polymorphisms (SNPs) influencing platelet aggregation during aspirin treatment. Furthermore, we explored to what extent changes in cyclooxygenase-1 activity and platelet activation may explain such influence. METHODS: We included 985 Danish patients with stable coronary artery disease treated with aspirin 75 mg/day mono antiplatelet therapy. Patients were genotyped for 16 common SNPs in platelet-related genes using standard PCR-based methods (TaqMan). Platelet aggregation was evaluated by whole blood platelet aggregometry employing Multiplate Analyzer (agonists: arachidonic acid and collagen) and VerifyNow Aspirin. Serum thromboxane B(2) was measured to confirm aspirin adherence and was used as a marker of cyclooxygenase-1 activity. Soluble P-selectin was used as marker of platelet activation. Platelet aggregation, cyclooxygenase-1 activity, and platelet activation were compared across genotypes in adjusted analyses. RESULTS: The A-allele of the rs12041331 SNP in the platelet endothelial aggregation receptor-1 (PEAR1) gene was associated with reduced platelet aggregation and increased platelet activation, but not with cyclooxygenase-1 activity. Platelet aggregation was unaffected by the other SNPs analyzed. CONCLUSION: A common genetic variant in PEAR1 (rs12041331) reproducibly influenced platelet aggregation in aspirin-treated patients with coronary artery disease. The exact biological mechanism remains elusive, but the effect of this polymorphism may be related to changes in platelet activation. Furthermore, 14 SNPs previously suggested to influence aspirin efficacy were not associated with on-aspirin platelet aggregation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01383304 Public Library of Science 2014-10-31 /pmc/articles/PMC4216141/ /pubmed/25360888 http://dx.doi.org/10.1371/journal.pone.0111816 Text en © 2014 Würtz et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Würtz, Morten
Nissen, Peter H.
Grove, Erik Lerkevang
Kristensen, Steen Dalby
Hvas, Anne-Mette
Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1
title Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1
title_full Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1
title_fullStr Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1
title_full_unstemmed Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1
title_short Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1
title_sort genetic determinants of on-aspirin platelet reactivity: focus on the influence of pear1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216141/
https://www.ncbi.nlm.nih.gov/pubmed/25360888
http://dx.doi.org/10.1371/journal.pone.0111816
work_keys_str_mv AT wurtzmorten geneticdeterminantsofonaspirinplateletreactivityfocusontheinfluenceofpear1
AT nissenpeterh geneticdeterminantsofonaspirinplateletreactivityfocusontheinfluenceofpear1
AT groveeriklerkevang geneticdeterminantsofonaspirinplateletreactivityfocusontheinfluenceofpear1
AT kristensensteendalby geneticdeterminantsofonaspirinplateletreactivityfocusontheinfluenceofpear1
AT hvasannemette geneticdeterminantsofonaspirinplateletreactivityfocusontheinfluenceofpear1